News

ISIS-TTR is an antisense drug intends for the treatment of transthyretin amyloidosis, a genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. For the ISIS-TTR

Auxilium produces products in the men’s healthcare segment, and has expanded its product portfolio and pipeline to orthopedics, dermatology and other therapeutic areas. Auxilium Pharmaceuticals CEO and president

The eye drops progressively deliver the right amount of drug-infused nanoparticles to the surface of the eyeball over a period of five days before the body absorbs them.

Funded by a contract with the NCI, HemoShear is developing a series of tumor models that recreate a wide variety of cancers for discovery of new drugs. Using

Join Bürkert industry experts and Business Review Webinars, on 25 November to learn more about valuable insights to help your business. The first of a series of webinars

The death toll has reached 3,439 in the worst Ebola-hit nations Guinea, Liberia, and Sierra Leone. The two-year regional financial impact could reach around $32.6bn by the end

The latest deal follows similar third-party deal already established with Nitto Medic in Japan for the distribution of AdenoPlus. The company has also established similar deals in Switzerland,

VELCADE is the first treatment in the United States to be approved for use in previously untreated patients with MCL. This approval extends the utility of VELCADE beyond

The latest partnership is a sales and distribution arrangement, which would allow Cipla Medpro to exclusively promote Teva’s broad pharmaceutical product portfolio in South Africa. Cipla Medpro chief